Campbell & CO Investment Adviser LLC Purchases Shares of 7,800 Seres Therapeutics Inc (NASDAQ:MCRB)

Campbell & CO Investment Adviser LLC acquired a new position in shares of Seres Therapeutics Inc (NASDAQ:MCRB) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 7,800 shares of the biotechnology company’s stock, valued at approximately $221,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Two Sigma Advisers LP boosted its holdings in Seres Therapeutics by 30.9% in the second quarter. Two Sigma Advisers LP now owns 116,900 shares of the biotechnology company’s stock valued at $556,000 after acquiring an additional 27,600 shares during the last quarter. Nuveen Asset Management LLC lifted its stake in shares of Seres Therapeutics by 10.9% in the 2nd quarter. Nuveen Asset Management LLC now owns 258,047 shares of the biotechnology company’s stock valued at $1,229,000 after purchasing an additional 25,372 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Seres Therapeutics by 6.8% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 415,888 shares of the biotechnology company’s stock valued at $1,980,000 after purchasing an additional 26,421 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its holdings in shares of Seres Therapeutics by 10.8% during the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 235,307 shares of the biotechnology company’s stock worth $1,120,000 after purchasing an additional 22,928 shares during the period. Finally, Jane Street Group LLC increased its position in Seres Therapeutics by 22.2% during the 2nd quarter. Jane Street Group LLC now owns 14,327 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 2,605 shares in the last quarter. Institutional investors and hedge funds own 94.42% of the company’s stock.

Shares of NASDAQ:MCRB opened at $34.05 on Friday. The firm has a market cap of $2.60 billion, a PE ratio of -32.74 and a beta of 4.33. The company has a fifty day simple moving average of $27.10 and a 200 day simple moving average of $11.77. Seres Therapeutics Inc has a 12-month low of $2.52 and a 12-month high of $35.02.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.02). The business had revenue of $6.05 million for the quarter, compared to the consensus estimate of $9.67 million. As a group, analysts forecast that Seres Therapeutics Inc will post -1.02 earnings per share for the current fiscal year.

Several research firms have issued reports on MCRB. Jefferies Financial Group upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $4.00 to $29.00 in a research note on Tuesday, August 11th. Piper Sandler began coverage on shares of Seres Therapeutics in a research report on Tuesday, August 18th. They set an “overweight” rating and a $40.00 price target for the company. HC Wainwright increased their price target on Seres Therapeutics from $8.00 to $41.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. BidaskClub upgraded Seres Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, September 17th. Finally, Zacks Investment Research cut shares of Seres Therapeutics from a “buy” rating to a “sell” rating in a research report on Thursday, July 30th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. Seres Therapeutics has a consensus rating of “Buy” and an average price target of $30.50.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Recommended Story: What are trading strategies for the 52-week high/low?

Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.